Takeda Said By U.S. FDA To Exaggerate Insomnia Drug Benefits
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical was admonished by the U.S. FDA, which said promotions for the Rozerem (ramelteon) insomnia drug are misleading